ArticleCancer gene therapy2026
TWF1 inhibition overcomes cisplatin resistance in NSCLC by inducing ferroptosis via p53-dependent SLC7A11 repression and autophagy-mediated glutathione metabolism reprogramming.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Non-small-cell lung cancer (NSCLC) ranks among the most prevalent causes of cancer-related mortality worldwide, with cisplatin-based chemotherapy being a cornerstone of clinical treatment despite the inevitable emergence of drug resistance. This study systematically investigated the molecular mechanisms underlying cisplatin resistance in NSCLC, focusing on the role of TWF1 in regulating ferroptosis. Mechanistic analyses revealed that TWF1 acts as a dual-function suppressor of ferroptosis. Through direct interaction with p53, TWF1 inhibits p53 nuclear translocation, thereby upregulating SLC7A11 and promoting system Xc⁻-mediated cystine uptake, which supports GSH biosynthesis and redox homeostasis. TWF1 induces autophagy-related metabolic reprogramming, increasing intracellular glutamate levels to sustain system Xc⁻ activity and suppress lipid peroxidation. In cisplatin-resistant A549/cisplatin (DDP) cells, TWF1 knockdown significantly reduced SLC7A11 expression, depleted GSH reserves, and enhanced lipid reactive oxygen species (ROS) accumulation, sensitizing cells to cisplatin via ferroptosis induction. This study identifies TWF1 as a critical regulator of cisplatin resistance and ferroptosis, highlighting the therapeutic potential of TWF1 inhibition combined with cisplatin to overcome chemoresistance, possibly providing new strategies for improving NSCLC treatment outcomes.
Indexed as
Identifiers
42754659What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.